# Survodutide

Source: https://aminodesk.com/library/survodutide
Publisher: Amino Desk
Updated: 2026-11-17
Clinical review: pending

Survodutide is an experimental weekly weight-loss injection from Boehringer Ingelheim and Zealand Pharma. It has finished several Phase 3 trials but, as of November 2026, is not approved for any use.

- **Legal lane:** investigational. Not approved in any country.
- **Evidence grade:** B
- **Form:** weekly injection under the skin
- **Also studied in:** fatty liver disease (MASH)

## What it is

Survodutide activates two receptors, GLP-1 and glucagon, the same pairing as [mazdutide](https://aminodesk.com/library/mazdutide). The glucagon side is meant to increase fat burning in the liver, which is why it is also being tested in liver disease.

## What the evidence shows

- **SYNCHRONIZE-1** (New England Journal of Medicine, 2026): 725 adults with obesity and no diabetes, treated for 76 weeks. Average weight loss was 12.2% on 3.6 mg and 13.0% on 6.0 mg, against 5.4% on placebo. Among people who stayed on the 6.0 mg dose, it was 16.6%.
- **SYNCHRONIZE-2:** in 752 adults with type 2 diabetes, the 6.0 mg dose produced 9.8% weight loss against 3.9% on placebo.
- **SYNCHRONIZE-CVOT** (The Lancet, November 2026): met its goal of showing no increase in heart and stroke risk.

These are large, well-run trials. The grade is B because the drug is not approved and its weight loss is smaller than the approved [tirzepatide](https://aminodesk.com/library/tirzepatide) in separate trials.

## Dosing used in the trials

There is no approved dose. Trials gave survodutide once a week and raised the dose gradually to a maintenance dose of 3.6 mg or 6.0 mg. The dose-raising period is where most side effects and dropouts happened, and newer trials use slower, more flexible schedules.

## Side effects

- Stomach and gut side effects were very common: 81% on 3.6 mg and 90% on 6.0 mg in SYNCHRONIZE-1, against 48% on placebo, mostly mild to moderate.
- In the diabetes trial, 18% of people on survodutide stopped because of them, against 1.2% on placebo.

## Legal status

Survodutide is not approved for any use. The FDA has named it among the drugs it has warned research-chemical sellers about.

## Common questions

### Is survodutide approved?

No. As of November 2026 it is not approved for any use in any country.

### How much weight did people lose on survodutide?

In SYNCHRONIZE-1, average weight loss over 76 weeks was 12.2% on 3.6 mg and 13.0% on 6.0 mg, against 5.4% on placebo.

### What are the side effects of survodutide?

Stomach and gut side effects were very common: 81% on 3.6 mg and 90% on 6.0 mg in SYNCHRONIZE-1, against 48% on placebo, mostly mild to moderate.

Added in the latest update. These answers summarize the sections above; sources are listed below.

## Sources

- [le Roux et al. 2026: SYNCHRONIZE-1, New England Journal of Medicine (PubMed)](https://pubmed.ncbi.nlm.nih.gov/42253238/)
- [SYNCHRONIZE-2: survodutide in adults with obesity and type 2 diabetes (University of Glasgow repository)](https://eprints.gla.ac.uk/396782/)
- [AJMC: SYNCHRONIZE-CVOT results, November 2026](https://www.ajmc.com/view/survodutide-meets-cv-safety-end-point-in-synchronize-cvot)
- [FDA: Concerns with unapproved GLP-1 drugs used for weight loss](https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss)

---
Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL.
